TUCSON, Ariz., Aug. 14, 2008 (PRIME NEWSWIRE) -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX), a biopharmaceutical company with a commercial product, urokinase, and a research and development program focused on the development of new treatments for vascular disorders leveraging its proprietary SonoLysis technology, today reported financial results for the quarter ended June 30, 2008.
